Skip to main content
Premium Trial:

Request an Annual Quote

Teranode Design Suite 2, GenBank release 144.0, HapMap data release 12, IBM Solution for Compliance in a Regulated Environment (SCORE)


Teranode has released three new products: Teranode Design Suite 2, a “closed-loop” R&D platform for integrating modeling into existing informatics infrastructures; Teranode Model Server, which provides a single repository for managing design through protocol development and experimentation to evaluation; and the Teranode Accelerator Development Kit, which contains an application programming interface, a library of existing integrations, and documentation.

GenBank release 144.0 is now available via ftp from the National Center for Biotechnology Information at The release contains 43,194,602,655 base pairs and 38,941,263 entries, up by 1,386,557,002 base pairs and by 1,597,326 sequence records (non-WGS) and 2,742,978,532 base pairs and by 857,503 sequence records (WGS) from the August 143.0 release. Uncompressed, the 144.0 flat files require about 147 GB for the sequence files only. The ASN.1 version requires around 128 GB.

HapMap data release 12 is now available from the HapMap Data Coordination Center at Cold Spring Harbor Laboratory at The release contains 752,208 genotype sets from the 90 CEPH-panel samples, totaling 67,698,720 genotypes, according to the organization.

IBM Healthcare and Life Sciences said they have launched the IBM Solution for Compliance in a Regulated Environment (SCORE). The technology is designed as a regulatory compliance system to help pharmaceutical, biotechnology, and medical device companies comply with regulatory mandates for R&D, manufacturing, and sales and marketing processes.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.